Response Of Bortezomib, Cyclophosphamide And Dexamethasone Induction Chemotherapy In Multiple Myeloma Patients Presenting To Combined Military Hospital Rawalpindi
DOI:
https://doi.org/10.51253/pafmj.v74i1.5777Keywords:
Bortezomib, Cyclophosphamide, Dexamethasone, Karnofsky performance status, Neutropenia, Febrile neutropenia, Chemotherapy-induced febrile neutropeniaAbstract
Objective: To determine the response rate and tolerability of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) induction therapy in multiple myeloma patients.
Study Design: Prospective longitudinal study
Place and Duration of Study: Department of Oncology, Combined Military Hospital, Rawalpindi Pakistan, from Mar to Sep 2020.
Methodology: Patients of either gender aged >20-65 years, newly diagnosed cases of multiple myeloma, Durie-Salmon stage II/III, were included. Patients were given Bortezomib, Cyclophosphamide and Dexamethasone induction therapy for a 21-day cycle. Response rate and tolerability were measured.
Results: A total of 147 patients were included in the study. There were 75(51%) male and 72(49%) female.The overall response rate was seen in 93(63.3%) patients, complete response was seen in 30(20.4%), and partial response was seen in 63(42.9%) patients. The overall response rate was significantly associated with age, myeloma type, and Karnofsky's performance status (p-value<0.001).
Conclusion: The novel sequential 3-drug combination of Bortezomib, Cyclophosphamide and Dexamethasone is safe and well tolerated for multiple myeloma patients. The results of the current study increase evidence of a moderately high response rate with Bortezomib, Cyclophosphamide and Dexamethasone induction therapy.
Downloads
References
Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE,
Cheung MC. Bortezomib in multiple myeloma: systematic
review and clinical considerations. Curr Oncol 2014; 21(4): e573-
https://doi.org/10.3747/co.21.1798
Goldschmidit H, Duerig J, Bertsch U, Kunz C, Hielscher T,
Haenel M, et al; German-speaking Myeloma Multicenter Group
(GMMG). Response-adapted lenalidomide maintenance in newly
diagnosed myeloma: results from the phase III GMMG-MM5
trial. Leukemia 2020; 34(7): 1853-1865.
https://doi.org/10.1038/s41375-020-0724-1
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR,
Plevak MF, et al. A long-term study of prognosis in monoclonal
gammopathy of undetermined significance. N Engl J Med 2002;
(8): 564-569. https://doi.org/10.1056/NEJMoa01133202
Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF,
Weisenburger D, et al. Familial myeloma. N Engl J Med 2008;
(2): 152-157. https://doi.org/10.1056/NEJMoa0708704
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE,
Hayes RB, et al.Monoclonal gammopathy of undetermined
significance (MGUS) consistently precedes multiple myeloma: a
prospective study. Blood 2009; 113(22): 5412-5417.
https://doi.org/10.1182/blood-2008-12-194241
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N,
Stewart AK, et al. International Myeloma Working Group
molecular classification of multiple myeloma: spotlight review.
Leukemia 2009; 23(12): 2210-2221.
https://doi.org/10.1038/leu.2009.174
Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez
R, Powles R. Soft-tissue plasmacytomas in multiple myeloma:
incidence, mechanisms of extramedullary spread, and treatment
approach. J Clin Oncol 2011; 29(28): 3805-3812.
https://doi.org/10.1200/JCO.2011.34.9290
Einsele H , Engelhardt M , Tapprich C , Müller J , Liebisch
P , Langer C, et al. Phase II study of bortezomib,
cyclophosphamide and dexamethasone as induction therapy in
multiple myeloma: DSMM XI trial. Br J Haematol 2017; 179(4):
-597. https://doi.org/10.1111/bjh.14920
Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The
combination of cyclophosphamide, velcade and dexamethasone
induces high response rates with comparable toxicity to velcade
alone and velcade plus dexamethasone. Haematologica 2007;
(8): 1149-1150. https://doi.org/10.3324/haematol.11228
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH,
Williams ME, et al; Eastern Cooperative Oncology Group.
Lenalidomide plus high-dose dexamethasone versus
lenalidomide plus low-dose dexamethasone as initial therapy for
newly diagnosed multiple myeloma: an open-label randomised
controlled trial. Lancet Oncol 2010; 11(1): 29-37.
https://doi.org/10.1016/S1470-2045(09)70284-0 Erratum in:
Lancet Oncol 2010;11(1):14.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ,
et al. Randomized, multicenter, phase 2 study (EVOLUTION) of
combinations of bortezomib, dexamethasone,
cyclophosphamide, and lenalidomide in previously untreated
multiple myeloma. Blood 2012; 119(19): 4375-4382.
https://doi.org 10.1182/blood-2011-11-395749
Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, et al.
Bortezomib, dexamethasone, cyclophosphamide and
lenalidomide combination for newly diagnosed multiple
myeloma: phase 1 results from the multicenter EVOLUTION
study. Leukemia 2010; 24(7): 1350-1356.https://doi.org
1038/leu.2010.116
Brenner H, Gondos A, Pulte D. Recent major improvement in
long-term survival of younger patients with multiple myeloma.
Blood 2008; 111(5): 2521-2526.https://doi.org 10.1182/blood2007-08-104984
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X,
Grishunina M, et al. Subcutaneous versus intravenous
administration of bortezomib in patients with relapsed multiple
myeloma: a randomised, phase 3, non-inferiority study. Lancet
Oncol 2011;12(5):431-440.https://doi.org 10.1016/S1470-
(11)70081-X Erratum in: Lancet Oncol 2011; 12(6): 522.
Leiba M , Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, et
al. Bortezomib-cyclophosphamide-dexamethasone (VCD) Versus
Bortezomib-Thalidomide-Dexamethasone (VTD) -Based
Regimens as Induction Therapies in Newly Diagnosed
Transplant Eligible Patients With Multiple Myeloma: A MetaAnalysis. Br J Haematol 2016; 166(5): 702-710.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ,
et al. Randomized, multicenter, phase 2 study (EVOLUTION) of
combinations of bortezomib, dexamethasone,
cyclophosphamide, and lenalidomide in previously untreated
multiple myeloma. Blood 2012; 119(19): 4375-4382.
https://doi.org 10.1182/blood-2011-11-395749
Bensinger IW, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin
D, et al. Phase 2 study of two sequential three-drug combinations
containing bortezomib, cyclophosphamide and dexamethasone,
followed by bortezomib, thalidomide and dexamethasone as
frontline therapy for multiple myeloma. Br J Haematol 2010;
(4): 562-568. https://doi.org 10.1111/j.1365-2141.2009.07981.x
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer
A, et al. Randomized phase III study of pegylated liposomal
doxorubicin plus bortezomib compared with bortezomib alone
in relapsed or refractory multiple myeloma: combination therapy
improves time to progression. J Clin Oncol 2007; 25(25): 3892-901.
https://doi.org 10.1200/JCO.2006.10.5460
Downloads
Published
Issue
Section
How to Cite
